Related Experiment Video
Updated: Sep 17, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
A Critical Appraisal of Lipid Management in the Post-Statin Era: Comparison on Guidelines, Therapeutic Targets, and
Jared Spitz1, Jaideep Patel2, Anandita Agarwala3
1Inova Schar Heart and Vascular, Inova Health System, Falls Church, Virginia, USA.
Insights
Managing cholesterol with statins and newer nonstatin therapies is crucial for preventing atherosclerotic cardiovascular disease (ASCVD). This review covers current lipid management guidelines and complex case studies for ASCVD risk reduction.
Area of Science:
- Cardiology and Lipidology
- Atherosclerotic Cardiovascular Disease (ASCVD) Pathogenesis
- Cholesterol Management Strategies
Background:
- Low-density lipoprotein-cholesterol (LDL-C) is a key factor in atherosclerotic cardiovascular disease (ASCVD) development.
- Lipid management is a fundamental approach to mitigating ASCVD.
- Numerous nonstatin therapies complement statin therapy for cholesterol management.
Purpose of the Study:
- To review current international lipid management recommendations.
- To present and discuss complex, common clinical cases in lipid management.
- To provide guidance on applying guideline-based and emerging evidence for ASCVD risk lipid management.
Main Methods:
- Expert panel review of international lipid management guidelines.
- Analysis of complex, real-world clinical scenarios.
- Integration of current evidence into management strategies.
Main Results:
- Established role of LDL-C in ASCVD pathogenesis.
- Availability of diverse nonstatin therapies for hypercholesterolemia.
- Need for expert guidance in applying guidelines to complex cases.
Conclusions:
- Current guidelines provide a framework for lipid management in ASCVD.
- Nonstatin therapies offer valuable options for achieving lipid goals.
- Expert interpretation and application of evidence are essential for optimal ASCVD risk management.
Abstract:
The role of low-density lipoprotein-cholesterol in the pathogenesis of atherosclerotic cardiovascular disease (ASCVD) is well established. Lipid management remains the cornerstone of addressing ASCVD. In addition to statin therapy, there is a large and growing number of nonstatin therapies available to manage elevated cholesterol levels. This expert panel seeks to review current international recommendations regarding lipid management. In addition, complex yet commonly encountered lipid-management cases are provided. Guidance on applying guideline-based recommendations as well as newer evidence to the evaluation and management of ASCVD-risk lipid management is then provided.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Angina IV: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

